PMID- 31763180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2214-7500 (Electronic)
IS  - 2214-7500 (Linking)
VI  - 6
DP  - 2019
TI  - Neuroprotective potential of solanesol in intracerebroventricular propionic acid 
      induced experimental model of autism: Insights from behavioral and biochemical 
      evidence.
PG  - 1164-1175
LID - 10.1016/j.toxrep.2019.10.019 [doi]
AB  - Autism is the category used within the newest edition of the diagnostic and 
      statistical manual of neurodevelopmental disorders. Autism is a spectrum of 
      disorder where a variety of behavioural patterns observed in autistic patients, 
      such as stereotypes and repetitive behavior, hyperexcitability, depression-like 
      symptoms, and memory and cognitive dysfunctions. Neuropathological hallmarks that 
      associated with autism are mitochondrial dysfunction, oxidative stress, 
      neuroinflammation, Neuro-excitation, abnormal synapse formation, overexpression 
      of glial cells in specific brain regions like cerebellum, cerebral cortex, 
      amygdala, and hippocampus. ICV injection of propionic acid (PPA) (4 mul/0.26 M) 
      mimics autistic-like behavioral and biochemical alterations in rats. Literature 
      findings reveal that there is a link between autism neuronal mitochondrial 
      coenzyme-Q10 (CoQ10) and ETC-complexes dysfunctions are the keys pathogenic 
      events for autism. Therefore, in the current study, we explore the 
      neuroprotective interventions of Solanesol (SNL) 40 and 60 mg/kg alone and in 
      combination with standard drugs Aripiprazole (ARP) 5 mg/kg, Citalopram (CTP) 
      10 mg/kg, Memantine (MEM) 5 mg/kg and Donepezil (DNP) 3 mg/kg to overcome 
      behavioral and biochemical alterations in PPA induced experimental model of 
      Autism. Chronic treatment with SNL 60 mg/kg in combination with standard drug 
      shows a marked improvement in locomotion, muscle coordination, long-term memory 
      and the decrease in depressive behavior. While, chronic treatment of SNL alone 
      and in combination with standard drug aripiprazole, citalopram, donepezil, and 
      memantine shows the Neuroprotective potential by enhancing the cognitive 
      deficits, biochemical alterations along with reducing the level of inflammatory 
      mediators and oxidative stress.
CI  - (c) 2019 The Authors.
FAU - Sharma, Ramit
AU  - Sharma R
AD  - Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.
FAU - Rahi, Saloni
AU  - Rahi S
AD  - Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.
FAU - Mehan, Sidharth
AU  - Mehan S
AD  - Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.
LA  - eng
PT  - Journal Article
DEP - 20191105
PL  - Ireland
TA  - Toxicol Rep
JT  - Toxicology reports
JID - 101630272
PMC - PMC6861559
OTO - NOTNLM
OT  - AChE, acetylcholinesterase acetylcholinesterase
OT  - ARP, Aripiprazole
OT  - ATP
OT  - Aripiprazole
OT  - Autism
OT  - BBB, blood-brain barrier
OT  - CNS, center nerves system
OT  - CTP, Citalopram
OT  - Citalopram
OT  - CoQ10, coenzyme-Q10
OT  - Coenzyme-Q10
OT  - DNP, Donepezil
OT  - Donepezil
OT  - ELT, escape latency
OT  - ETC, electron-transport chain
OT  - ICV, Intracerebroventricular
OT  - LDH, lactate dehydrogenase
OT  - MAPK3, mitogen-activated protein kinase 3
OT  - MDA, malondialdehyde
OT  - MEM, Memantine
OT  - Memantine
OT  - NO, nitric oxide
OT  - PPA, propionic acid
OT  - Propionic acid
OT  - SNL, Solanesol
OT  - SOD, superoxide dismutase
OT  - UBE3A, Ubiquitin-protein ligase E3A
OT  - i.p., Intraperitoneal route
OT  - mitochondrial dysfunction
OT  - p.o., Oral
EDAT- 2019/11/26 06:00
MHDA- 2019/11/26 06:01
PMCR- 2019/11/05
CRDT- 2019/11/26 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2019/10/18 00:00 [revised]
PHST- 2019/10/21 00:00 [accepted]
PHST- 2019/11/26 06:00 [entrez]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2019/11/26 06:01 [medline]
PHST- 2019/11/05 00:00 [pmc-release]
AID - S2214-7500(19)30361-0 [pii]
AID - 10.1016/j.toxrep.2019.10.019 [doi]
PST - epublish
SO  - Toxicol Rep. 2019 Nov 5;6:1164-1175. doi: 10.1016/j.toxrep.2019.10.019. 
      eCollection 2019.